India Secures US Tariff Relief for Specialty Pharmaceutical Products
Washington — India has been included among countries eligible for zero U.S. tariffs on several categories of specialty pharmaceutical products and ingredients, providing targeted relief for one of the largest suppliers of medicines to the American market.
The U.S. Commerce Department published the list as Washington prepares to impose a 100% tariff on certain patented pharmaceutical imports and related ingredients beginning September 29.
The exemption does not apply to all pharmaceutical products exported from India. It covers specific medicines and ingredients included under a presidential proclamation issued in April.
Eligible products include orphan drugs, nuclear medicines, plasma-derived therapies, fertility drugs, cell therapies, gene therapies and antibody-drug conjugates.
The exemption also extends to certain medical countermeasures related to chemical, biological, radiological and nuclear threats, as well as some animal-health products.
India was listed alongside Argentina, Bangladesh, Cambodia, Ecuador, El Salvador, the European Union, Guatemala, Indonesia, Japan, Jordan, Malaysia, North Macedonia, South Korea, Switzerland and Liechtenstein, Taiwan, Thailand, Britain and Vietnam.
According to the Commerce Department notice, qualifying products from these jurisdictions may receive a zero tariff because they have an existing or forthcoming trade and security framework agreement with the United States.
The exemptions are part of the implementation of President Donald Trump’s April proclamation adjusting imports of pharmaceuticals and pharmaceutical ingredients under Section 232 of the Trade Expansion Act.
The proclamation imposed a 100% tariff on specified patented pharmaceuticals and ingredients. The tariff took effect July 31 for companies listed in one annex and will apply to other covered companies beginning September 29.
Generic pharmaceutical products and their associated ingredients are not subject to the Section 232 pharmaceutical tariffs, according to the Commerce Department.
That distinction is significant for India because a large portion of its pharmaceutical exports to the United States consists of generic medicines. Indian companies also manufacture patented drugs, active pharmaceutical ingredients and specialized therapies.
The exemption provides Indian manufacturers with a route to maintain duty-free access for certain high-value therapies even as the United States uses tariffs to encourage more pharmaceutical production domestically.
India is one of the world’s largest producers of generic medicines and a major supplier to the U.S. healthcare system. Indian companies also provide active pharmaceutical ingredients and finished formulations used by hospitals, pharmacies and patients across the country.
Pharmaceutical trade has become an important part of the broader India-U.S. economic relationship, with the latest exemption protecting selected specialty medicines while leaving Washington’s wider push to expand domestic drug manufacturing in place. (Source: IANS)
